Precision diagnosis and treatment of recurrent spontaneous abortion with insulin resistance

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036545

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent spontaneous abortion with insulin resistance

Interventions

Experimental gro:Metformin

Control group:Placebo

Eligibility

Sex/Gender

Female

Age

25 Years to 35 Years

Inclusion criteria

Inclusion criteria: (1) Women aged 25 to 35 years; (2) Patients diagnosed with RSA was previously defined as two or more consecutive clinically recognized spontaneous pregnancy losses before 20wk of gestation. (3) Meet the diagnostic criteria for insulin resistance. (4) Informed consent was signed.

Exclusion criteria

Exclusion criteria: (1) Couples with chromosomal abnormalities; (2) Uterine and fallopian tube factors; (3) Diabetes (refer to the diagnostic criteria issued by the World Health Organization in 2019); (4) PCOS (reference Expert consensus on diagnosis and treatment of polycystic ovary syndrome); (5) Currently taking metformin; (6) Metformin allergy; (7) Abnormal liver and kidney function and heart function; (8) Planning IVF/ICSI treatment.

Design outcomes

Primary

Measure	Time frame
pregnant outcome;OGTT;IGT;	—

Countries

China

Contacts

Public ContactBao Shihua

Shanghai First Maternity and Infant Hospital

baoshihua@tongji.edu.cn+86 13916772579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026